This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut University Hospitals.
Secondary hyperparathyroidism is a common complication of end-stage renal disease and is associated with bone disease, vascular calcification, and increased mortality. Dialysis adequacy, measured by spKt/V and urea reduction ratio (URR), may influence phosphate control and parathyroid hormone levels. This observational cross-sectional study will include adult patients with end-stage renal disease maintained on regular thrice-weekly hemodialysis for at least three months. Dialysis adequacy will be assessed by spKt/V and URR. Serum intact parathyroid hormone (iPTH) and mineral parameters will be measured.
Study Type
OBSERVATIONAL
Enrollment
130
Prevalence of secondary hyperparathyroidism
Proportion of patients with elevated intact parathyroid hormone (iPTH) levels above the target range (greater than 9 times the upper limit of normal) among regular hemodialysis patients.
Time frame: Baseline
Prevalence of adequate dialysis
Proportion of patients achieving target dialysis adequacy defined as single-pool Kt/V (spKt/V) ≥ 1.2 or urea reduction ratio (URR) ≥ 65%.
Time frame: Baseline
Correlation between dialysis adequacy and iPTH level
Correlation coefficient between dialysis adequacy parameters (spKt/V and URR) and serum intact parathyroid hormone (iPTH) levels, using Spearman or Pearson correlation as appropriate.
Time frame: Baseline
Serum phosphate levels according to dialysis adequacy
Mean serum phosphate concentration (mg/dL) in patients with adequate versus inadequate dialysis.
Time frame: Baseline
Serum calcium level
Mean serum calcium concentration (mg/dL) in patients with secondary hyperparathyroidism.
Time frame: Baseline
Serum phosphate level
Mean serum phosphate concentration (mg/dL) in patients with secondary hyperparathyroidism.
Time frame: Baseline
Serum alkaline phosphatase level
Mean serum alkaline phosphatase concentration (U/L) in patients with secondary hyperparathyroidism.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Calcium-phosphorus product
Mean calcium-phosphorus product (mg²/dL²) in patients with secondary hyperparathyroidism.
Time frame: Baseline